Tandem Diabetes Care 

$16.76
77
+$0.16+0.96% Today

Statistics

Day High
17.01
Day Low
16.31
52W High
29.65
52W Low
9.98
Volume
1,609,290
Avg. Volume
2,354,244
Mkt Cap
1.15B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5AugExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Next
-0.67
-0.44
-0.22
0.01
Expected EPS
-0.32897
Actual EPS
N/A

Financials

-20.17%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
2.03BRevenue
-409.42MNet Income

Analyst Ratings

29.07Average Price Target
The highest estimate is 55.00.
From 15 ratings within the last 6 months. This is not an investment recommendation.
Buy
40%
Hold
60%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TNDM. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Dexcom
DXCM
Mkt Cap29.08B
Dexcom produces continuous glucose monitoring systems, directly competing in the diabetes management space with Tandem's insulin pumps.
Insulet
PODD
Mkt Cap10.37B
Insulet Corporation offers the Omnipod, an insulin management system that competes with Tandem's insulin pump products.
Medtronic
MDT
Mkt Cap102.97B
Medtronic is a major player in the diabetes care market, offering insulin pumps and continuous glucose monitoring systems that compete with Tandem's offerings.
Abbott Laboratories
ABT
Mkt Cap153.59B
Abbott Laboratories produces the FreeStyle Libre, a continuous glucose monitoring system, competing in the broader diabetes management market.
Senseonics
SENS
Mkt Cap374.82M
Senseonics Holdings offers the Eversense CGM system, a direct competitor in the continuous glucose monitoring market.
Thermo Fisher Scientific
TMO
Mkt Cap174.42B
Thermo Fisher Scientific, through its life sciences solutions, indirectly competes in the diabetes care market by providing technologies and supplies that support diabetes research and diagnostics.
Novo Nordisk
NVO
Mkt Cap194.35B
Novo Nordisk is a leading global healthcare company that, while primarily known for its diabetes medications, also invests in diabetes care devices and solutions, positioning it as a broader competitor.
Sanofi
SNY
Mkt Cap105.92B
Sanofi is involved in diabetes care through its insulin and glucose monitoring solutions, making it a competitor in the diabetes management space.
Baxter International
BAX
Mkt Cap10.77B
Baxter International offers medical devices that, while not directly competing in the insulin pump or CGM markets, provide various healthcare solutions that can be used in diabetes care.
Johnson & Johnson
JNJ
Mkt Cap579.83B
Johnson & Johnson, through its medical devices and pharmaceutical segments, has interests in the diabetes market, making it a broader competitor in the healthcare space for diabetes management.

About

Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.
Show more...
CEO
Mr. John F. Sheridan
Employees
2650
Country
United States
ISIN
US8753722037

Listings

0 Comments

Share your thoughts

FAQ

What is Tandem Diabetes Care stock price today?
The current price of TNDM is $16.76 USD — it has increased by +0.96% in the past 24 hours. Watch Tandem Diabetes Care stock price performance more closely on the chart.
What is Tandem Diabetes Care stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Tandem Diabetes Care stocks are traded under the ticker TNDM.
Is Tandem Diabetes Care stock price growing?
TNDM stock has fallen by -9.26% compared to the previous week, the month change is a +30.73% rise, over the last year Tandem Diabetes Care has showed a -19.27% decrease.
What is Tandem Diabetes Care market cap?
Today Tandem Diabetes Care has the market capitalization of 1.15B
When is the next Tandem Diabetes Care earnings date?
Tandem Diabetes Care is going to release the next earnings report on August 05, 2026.
What were Tandem Diabetes Care earnings last quarter?
TNDM earnings for the last quarter are -0.3 USD per share, whereas the estimation was -0.44 USD resulting in a +32.8% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Tandem Diabetes Care revenue for the last year?
Tandem Diabetes Care revenue for the last year amounts to 2.03B USD.
What is Tandem Diabetes Care net income for the last year?
TNDM net income for the last year is -409.42M USD.
How many employees does Tandem Diabetes Care have?
As of June 15, 2026, the company has 2,650 employees.
In which sector is Tandem Diabetes Care located?
Tandem Diabetes Care operates in the Health & Wellness sector.
When did Tandem Diabetes Care complete a stock split?
The last stock split for Tandem Diabetes Care was on October 10, 2017 with a ratio of 1:10.
Where is Tandem Diabetes Care headquartered?
Tandem Diabetes Care is headquartered in San Diego, United States.